Shop
eStoreRx™
Online Supplement Dispensary
Easy direct-to-patient ordering & fulfilment for Lifelong Wellness, eStoreRx™ is offered as part of the WholePractice membership or as a stand-alone program.
For over 40 years, Biotics Research Corporation has revolutionized the nutritional supplement industry by utilizing “The Best of Science and Nature”. Combining nature’s principles with scientific ingenuity, our products magnify the nutritional
This inclusive membership contains all of the the tools you need to grow your business, including WholeLifeRx™, Nimativ®, WholeLifeQ™, eStoreRx™ and Practice Success Programs.
Easy direct-to-patient ordering & fulfilment for Lifelong Wellness, eStoreRx™ is offered as part of the WholePractice membership or as a stand-alone program.
November 04 2024
Despite its widespread use, on an individual basis (in contrast to a population) body mass index (BMI) has several limitations related to risk predict...
A retrospective case series review of people with Crohn’s disease (CD) and ulcerative colitis (UC) whose symptoms weren’t controlled by traditional pharmaceutical therapies showed a symptom improvement rate of 76% after 12 weeks of taking serum-derived bovine immunoglobulin (SBI).
Crohn’s disease is a relapsing, chronic, systemic, transmural inflammatory condition that can involve the entire gastrointestinal tract. Symptoms can be very varied, even including fever, mouth sores, and inflammation in the joints, skin, eyes, bile ducts and liver. Ulcerative colitis, on the other hand, can be transmural in later stages, but tends to affect the mucosa only, leading to systemic symptoms such as rectal tenesmus, which is the sensation of incomplete evacuation of the bowel. Clinically, SBI has been shown to reduce many of the symptoms of irritable bowel syndrome with diarrhea (IBD-D) previous to this study. Case studies have also been able to identify multiple benefits of SBI in drug-refractory IBS-D patients, including endoscopic remission, yet further exploration in human subjects is needed to confirm the types of benefits for the CD and UC patient population.
This study explored symptoms management in IBD patients over 12 weeks using a Likert scale and regression model following 5 grams SBI per day for nutritional support.
The odds ratio from the regression model demonstrated that the patients were 2.8 times more likely to report improvements in symptoms when taking the SBI (those improvements were not significantly related to gender, race or disease state). What’s more, the improvements increased steadily between weeks 1 and 12. Forty-nine percent of the cases reported a positive response to the therapy during the first week. By week 12, 76% had seen an improvement in their symptoms.
The scientists behind the study suggest that SBI should be considered for use in the nutritional support of IBD regardless of disease location, phenotype, duration, activity or complexity.
Submit this form and you'll receive our latest news and updates.
A pilot study has provided evidence of the cost-saving benefits of the incorporation of serum-derived bovine immunoglobu...
Learn moreCompelling research has shown positive outcomes for patients suffering from pouchitis using Serum-Derived Bovine Immunog...
Learn moreA case series of 10 patients with long-standing, symptomatic, intractable drug-refractory irritable bowel syndrome (IBS)...
Learn more
*These statements have not been evaluated by the Food and Drug Administration. This product has not intended to diagnose, treat, cure, or prevent any disease.
© 2023 Biotics Research Corporation - All Rights Reserved
Submit your comment